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Chronic cluster headache (CCH) often resists to prophylactic pharmaceutical treatments resulting in patients’ life
damage. In this rare but pragmatic situation escalation to invasive management is needed but framing criteria are
lacking. We aimed to reach a consensus for refractory CCH definition for clinical and research use. The preparation
of the final consensus followed three stages. Internal between authors, a larger between all European Headache
Federation members and finally an international one among all investigators that have published clinical studies on
cluster headache the last five years. Eighty-five investigators reached by email. Proposed criteria were in the format
of the International Classification of Headache Disorders III-beta (description, criteria, notes, comments and references).
Following this evaluation eight drafts were prepared before the final. Twenty-four (28.2%) international investigators
commented during two rounds. Refractory CCH is described in the present consensus as a situation that fulfills the
criteria of ICHD-3 beta for CCH with at least three severe attacks per week despite at least three consecutive trials
of adequate preventive treatments. The condition is rare, but difficult to manage and invasive treatments may be
needed. The consensus addresses five specific clinical and paraclinical diagnostic criteria followed by three notes
and specific comments. Although refractory CCH may be not a separate identity these specific diagnostic criteria
should help clinicians and investigators to improve patient’s quality of life.
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Cluster headache (CH) is a rare but severe primary
headache with a circadian and circannual pattern, char-
acterized by periorbital unilateral pain and untreated
headache attacks shorter than 3 hours accompanied by
ipsilateral autonomic symptoms. It belongs into the
Trigeminal Autonomic Cephalalgias (TACs) category
of Primary Headache Disorders [1]. Depending on the
attack frequency CH is classified into episodic (ECH)
and chronic CH (CCH). About one person every 1,000
adults experiences CH. Males are affected four times
more often than females overall, but this difference in-
creases up to 15 holds in the case of chronic CH. Episodic
CH is six times more common than CCH. The prevalence* Correspondence: dimosmitsikostas@me.com
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in any medium, provided the original work is pseems to be stable among adult ages and countries [2].
For a proportion of patients a genetic predisposition has
been hypothesized as 2% to 7% of patients have one or
more affected relatives [3]. The evolution from an episodic
form can require years but CH can also be chronic since
its onset. It has been observed that one out of three pa-
tients with ECH at onset will develop CCH 10 years later.
On the other hand, the same proportion of patients with
CCH at onset turns into episodic within 10 years later
while nearly the half with CCH at onset still has CCH
after 20 or more years [4]. Because of its severity CH has a
large socioeconomic impact and associated morbidity; al-
most 80% of patients report restricting daily activities [5].
Among headache sufferers seeking neurological con-
sultation in Europe only 3% suffer from CH, though in
primary care settings this percentage falls to 1% [6], indi-
cating that CH is largely misdiagnosed [7,8]. The socio-
economic burden of CH on the individual and society isis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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the indirect costs of lost workdays and decreased work
efficacy. In Denmark has been estimated that less than
50% of CH patients are treated by headache specialists,
approximately 30% had missed work and 78% report re-
strictions in daily living [9]. In Germany the annual cost
of a single CCH patient is over €21,000 [10]. Yet the per-
sonal burden is enormous for those patients who do not
respond to treatment, since CH is a highly disabling
condition with pain that ranks among the most severe
known to humans [11,12].
Why do we need criteria to define refractory chronic
Cluster Headache?
1. Severity of attacks varies largely in CCH patients.
According to the ICHD-3 beta CCH is defined as a con-
dition with attacks occurring without a remission period,
or with remissions lasting <1 month, for at least 1 year [1].
This definition does not considerate the wide range of se-
verity of the condition, as a patient could have three attacks
a month or three attacks a day, in both cases for a year or
more. A further definition that takes into account the dis-
ability caused by CCH may be needed.
2. Available treatments are not always efficient leaving
patients without pain remission.
Treatments with a good clinical experience for the pre-
vention of CCH and/or that showed efficacy over placebo
in RCTs include verapamil, lithium, oral or iv steroids,
greater occipital nerve infiltration, topiramate, methyser-
gide, ergots, civamide and long acting triptans. Among
them verapamil has better documentation [13,14]. Some
agents may be not available across all European countries,
others require special monitoring (e.g. verapamil, lithium,
methysergide) or appropriate clinical experience (e.g. greater
occipital nerve infiltration). Nevertheless patients may not
respond to the above treatments. How often this happens
remains unknown, but all specialists agree that a propor-
tion of CCH patients do sometimes fail to manage their
headache attacks. The urgency of the clinical situation atFigure 1 Methodology used for the preparation and evaluation of crithat point has led physicians and patients to try unusual
treatments, and for most of these remedies, evidence is
sparse [15]. Therefore is essential to provide specific tools
for treatment escalation and scientific documentation of
second line treatments, including the invasive ones.
Preparation and evaluation
Because of the above mentioned reasons the European
Headache Federation Executive Board (EB) appointed a
committee to establish diagnostic criteria for refractory
CCH (rCCH). The first draft was discussed internally
and approved by the EB. Two stages were followed for
evaluation. In the first one the proposed criteria were
sent to all representatives of the National Headache So-
cieties of Europe for review. In a second evaluation step,
all international investigators that have clinical published
studies on CH were contacted for review (first and/or
corresponding authors) by email. Among 85 reached 24
(28.2%) investigators listed, in the Acknowledgments
section, commented and participated in a long discussion
during two rounds (Figure 1), before ending the prepar-
ation of the manuscript that was then approved by all
committee members (Appendix).
Discussion
We present here (Appendix) the EHF Diagnostic Criteria
for rCCH, after evaluation within EHF members of and
international investigators, suggesting a specific category
of TACs under the term of Cluster Headache in ICHD-3.
The current ICHD-3 beta does not include a definition
of refractoriness for primary headaches. Even if a shared
definition of refractoriness has already been claimed so
far no consensus regarding it has emerged. The debate
on what should be the key parameter for a definition of
refractoriness is still open (e.g., unresponsiveness to pre-
ventive treatment, high frequency, severe disability, in-
tolerance to current treatments, or all of these features).
Considering rCCH as an evolution of CCH, we can
hypothesize the inclusion of rCCH as a 3-digit diagno-
sis of CCH (3.1.3 Refractory chronic cluster headache).
We understand that ICHD is mainly deterministic rather
than phenotypic and includes only common sub-forms of
primary headache disorders, but in case of rCCH theteria.
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special care and management [11].
An important issue is the frequent presence of comor-
bidities. Depression and anxiety disorders represent undis-
putable co-factors in the progression of CH and require
adequate treatment [16]. Other brain conditions, mainly
vascular, should be carefully ruled out by appropriate in-
vestigation, including the carotid dissection [17-19]. CCH
sufferers often overuse symptomatic medications to treat
CH attacks and may develop medication overuse head-
ache (MOH) in addition. In this case headaches have
different phenotype than CH attacks, however, they
occur primarily in patients with migrainous predispos-
ition (ICHD-3 beta criteria) and require appropriate
management [20]. Behaviours exaggerating CH attacks
like alcohol consumption, smoking, taking naps, vaso-
dilating antihypertensives should be avoided [21]. The
indomethacin test is recommended to exclude paroxysmal
hemicrania, since there are cases with overlapping clinical
pictures [17,22]. Investigation with polysomnography may
be useful to exclude several rare conditions that may
exaggerate CCH [23,24]. Preventive medication should
be preferably used as monotherapy but a combination
is suggested when one preventive treatment is not
completely effective [7]. However, care must be taken
to avoid potentially negative drug interactions. There
is evidence that nocebo is very prevalent among head-
ache sufferers [25,26] and should be taken into account
before treatment escalation for safety reasons.
Recently the EHF proposed new criteria for the defin-
ition of refractory chronic migraine [27]. With the same
spirit, EHF members felt the need to develop new con-
sensus criteria that define rCCH. The operational pur-
poses of that classification are many, as RCTs involve
experimental medication and neuromodulation, medical
cost reimbursement, screening tool for invasive treat-
ment or implantable devices. The new frontier for the
treatment of the subset of patients with rCCH could be
neuromodulation, an interesting approach but still not
sufficiently validated [28].
Conclusion
In conclusion, this consensus suggests the publication of
these criteria as an Appedix in the ICHD-3 beta for a
worldwide validation hopefully before their inclusion in
the main body of the classification.
Appendix
EHF Diagnostic Criteria for refractory chronic cluster
headache
Description:
Chronic cluster headache with at least three severe at-
tacks per week despite at least three consecutive trials of
adequate preventive treatments have been tested. Thecondition is rare, but difficult to manage and invasive
treatments may be needed.
Diagnostic criteria:
A. Headache attacks fulfilling the ICHD-3 beta criteria
for chronic cluster headache (CCH), or probable
cluster headache (CH) and B-E criteria.
B. At least three severe CH attacks per week that
impact patients’ quality of life despite preventive or
symptomatic treatment.
C. Failed consecutive prophylactic treatment trials
with at least three agents that showed efficacy over
placebo in randomized controlled studies, used at
the maximum tolerated dose over a sufficient period
of time.
D. Symptomatic CCH is ruled out by negative
investigation with brain MRI and MRA, eventually
supplemented with carotid CT angiograms or triplex
carotid ultrasound.
E. Not better accounted for by another ICHD-3 beta
diagnosis.
Notes:
1. Treatments with a good clinical experience for the
prevention of CCH and/or that showed efficacy
over placebo in RCTs include verapamil, lithium, oral
or iv steroids, greater occipital nerve infiltration,
topiramate, methysergide, ergots, civamide and long
acting triptans. Among them verapamil has better
documentation. Some agents may be not available
across all European countries.
2. Combinations of suggested preventive treatments
are recommended especially when one preventive
treatment decreased the attack frequency but did
not controlled the situation satisfactorily, upon the
physician’s decision.
3. Several preventive treatments require special
monitoring (e.g. verapamil, lithium, methysergide)
or appropriate clinical experience (e.g. greater occipital
nerve infiltration).
Comments:
Other primary headache disorders that may mimic
and/or overlap with CCH include persistent idiopathic
facial pain (PIFP), SUNA, SUNCT, cluster-tic syndrome
or paroxysmal hemicrania (PH); these conditions should
be ruled out and/or treated for the patient to become
headache-free. The indomethacin test is recommended
to exclude PH. Investigation with polysomnography
may be useful to exclude several rare conditions that
may exaggerate CCH. CCH sufferers often overuse symp-
tomatic medications to treat CH attacks and may develop
medication overuse headache (MOH) in addition. In this
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occur primarily in patients with migrainous predisposition
(ICHD-3 beta criteria) and require appropriate manage-
ment. When recurrent CH attacks persist despite the pre-
ventive treatment but respond to acute symptomatic, the
treating physician together with the patient makes the de-
cision for treatment escalation individually, upon the pa-
tients’ preferences and consequences in his/her personal
quality of life. In this case, the situation is considered as re-
fractory CCH as well (criterion B). Special attention to the
management of simultaneous depression or other psychi-
atric comorbidities and nocebo behaviors is recommended.
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